Google
REPL 株価分析 — REPLIMUNE GROUP INC (Healthcare >> Biotechnology)
REPL に関するよくある質問
REPLのROE（自己資本利益率）は？
REPLIMUNE GROUP INCのROEは-188.94%です。
REPLの配当利回りは？
REPLIMUNE GROUP INCの配当利回りは0.00%です。
REPLの品質スコア（Quality Score）は？
当社のAIはREPLの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
REPLは今が買い時ですか？
当社AIのタイミングスコアは100点中55点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
REPLはどのセクターに属しますか？
REPLIMUNE GROUP INCはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
REPL AI Analysis Summary
Our AI summary for REPL: REPLIMUNE GROUP INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -188.94%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 11.20
Price
5.79
(107.02%)
Day Change
|
|
|---|
REPL, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 92 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 11.20 |
| PBV / Sector |
6.26 / 5.20
|
| Earning Per Share | -3.38 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
57.22 M
|
| Average 1W Daily Value |
136.64 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:24 |
| Symbol | REPL |
| Name | REPLIMUNE GROUP INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 84.03 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,039.40 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 500 Unicorn Park Drive, Woburn, MA, United States, 01801
Phone: 781 222 9600
Website: https://www.replimune.com
Employees: 465
Sector: Healthcare >> Biotechnology
Description: Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
